An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

    February 2018 in “ Journal of Investigative Dermatology ”
    Ali Jabbari, Freda Sansaricq, Jane Cerise, James C. Chen, Avi Bitterman, Grace Ulerio, J. Borbon, Raphael Clynes, Angela M. Christiano, Julian Mackay‐Wiggan
    Image of study
    TLDR Tofacitinib may help treat severe hair loss, but more research is needed.
    In a pilot study from July 1, 2018, Tofacitinib, a JAK inhibitor, was evaluated for its efficacy in treating moderate to severe alopecia areata (AA), totalis (AT), and universalis (AU) in 12 patients, with 11 completing the study. Initially prescribed at 5mg twice daily, the dosage was increased to 10mg for non-responders. The results showed that 8 patients experienced ≥50% hair regrowth, 3 had <50% regrowth, and 1 showed no regrowth, as measured by the Severity of Alopecia Tool (SALT) score, with the average time to reach the primary efficacy endpoint being 32 weeks. The study concluded that Tofacitinib could be a potential treatment for AA, as gene expression profiles and Alopecia Areata Disease Activity Index (ALADIN) scores correlated with clinical response, but it noted the need for larger trials to confirm these findings. The study was limited by its small sample size and open-label design.
    Discuss this study in the Community →

    Research cited in this study

    6 / 6 results

    Related Community Posts Join

    6 / 15 results
      Compressed part of research of theory of androgenic/anabolitic balance. AGA h-responders analytic. Theory of physio-metabolitic method of anti AGA treatment

      community Compressed part of research of theory of androgenic/anabolitic balance. AGA h-responders analytic. Theory of physio-metabolitic method of anti AGA treatment

      by MagicBold in Research  865 upvotes 1 year ago
      The treatment for androgenetic alopecia involves using finasteride and minoxidil with intense exercise and cold exposure to boost metabolism and reduce androgenic effects, potentially leading to hair regrowth. This approach may activate biological pathways for improved hair and overall health.

      community What else is good. Besides the big 3.

      in Chat  35 upvotes 1 year ago
      Key treatments for hair preservation include minoxidil, finasteride/dutasteride, and microneedling, with additional options like specific shampoos, oils, biotin, zinc, tretinoin, clascoterone, and low-level laser therapy. Maintaining a healthy lifestyle, reducing stress, and addressing nutrient deficiencies can also support hair health.

      community 22F. Should I even bother getting a biopsy? Is there any point?

       6 upvotes 9 years ago
      A woman who has been experiencing hair loss for several years, and her question of whether there is any benefit to getting a biopsy to check if it's AGA or diffuse alopecia areata when no cure or very effective treatment exists. Treatments such as spironolactone and Minoxidil/finasteride/RU58841 have previously been discussed.

      community Xeljanz....the magic drug!!!

       2 upvotes 7 years ago
      A user experienced significant hair regrowth from Xeljanz after severe alopecia but can no longer afford it. They are seeking ways to obtain the medication despite its high cost and potential side effects.

      community can someone help me identify these pls

      in Treatment 3 months ago
      The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

      community DUPA, Non Responders and Connective Tissue Disorders

      in Research/Science  9 upvotes 9 months ago
      A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.

    Related Research

    1 / 1 results